Insider Sale of 1% of MPLT Stock by MapLight Therapeutics' CDO Ahead of 2026 Trial Data
Anatol Kreitzer, the chief discovery officer of MapLight Therapeutics (NASDAQ:MPLT), sold 1% of his direct Common Stock holdings, amounting to 3,316 shares valued at approximately $88,000. The transaction is considered routine liquidity management and does not indicate a strategic shift in ownership. The company is preparing for 2026 trial data, which may influence future stock performance.
Topics: insider trading MapLight Therapeutics SEC Form 4 stock sales